One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Journals package 3months
-
http://medilib.ir
- Duration of Time : 93 Day
- :
Price : 100$- Special Price : 50$
Referral of patients with suspected polymyalgia rheumatica: how complete is our view of ‘planet PMR?‘
doi : 10.1136/ard-2023-225217
HLA-B27 and the role of specific T cell receptors in the pathogenesis of spondyloarthritis
doi : 10.1136/ard-2024-225661
From fibrositis to fibromyalgia to nociplastic pain: how rheumatology helped get us here and where do we go from here?
doi : 10.1136/ard-2023-225327
Recommendations for early referral of individuals with suspected polymyalgia rheumatica: an initiative from the international giant cell arteritis and polymyalgia rheumatica study group
doi : 10.1136/ard-2023-225134
EULAR recommendations for the involvement of patient research partners in rheumatology research: 2023 update
doi : 10.1136/ard-2024-225566
Olokizumab plus methotrexate: safety and efficacy over 106 weeks of treatment
doi : 10.1136/ard-2023-225473
Itaconate is a metabolic regulator of bone formation in homeostasis and arthritis
doi : 10.1136/ard-2023-224898
Treatment of early oligoarticular psoriatic arthritis with apremilast: primary outcomes at week 16 from the FOREMOST randomised controlled trial
doi : 10.1136/ard-2024-225833
Management of systemic lupus erythematosus: a systematic literature review informing the 2023 update of the EULAR recommendations
doi : 10.1136/ard-2023-225319
Efficacy and safety of sequential therapy with subcutaneous belimumab and one cycle of rituximab in patients with systemic lupus erythematosus: the phase 3, randomised, placebo-controlled BLISS-BELIEVE study
doi : 10.1136/ard-2024-225686
Racial variability in immune responses only partially explains differential systemic sclerosis disease severity
doi : 10.1136/ard-2023-225458
Association between premature vascular smooth muscle cells senescence and vascular inflammation in Takayasu's arteritis
doi : 10.1136/ard-2024-225630
Defects in B-lymphopoiesis and B-cell maturation underlie prolonged B-cell depletion in ANCA-associated vasculitis
doi : 10.1136/ard-2024-225587
Safety and efficacy of tofacitinib for the treatment of patients with juvenile idiopathic arthritis: preliminary results of an open-label, long-term extension study
doi : 10.1136/ard-2023-225094
Allogenic bone marrow–derived mesenchymal stromal cell–based therapy for patients with chronic low back pain: a prospective, multicentre, randomised placebo controlled trial (RESPINE study)
doi : 10.1136/ard-2024-225771
Factors associated with disease flare following SARS-CoV-2 vaccination in people with inflammatory rheumatic and musculoskeletal diseases: results from the physician-reported EULAR Coronavirus Vaccine (COVAX) Registry
doi : 10.1136/ard-2024-225869
Clinical efficacy and autoantibody seroconversion with CD19-CAR T cell therapy in a patient with rheumatoid arthritis and coexisting myasthenia gravis
doi : 10.1136/ard-2024-226017
Dysregulation of immune checkpoint molecules as a characteristic of autoimmune congenital heart block
doi : 10.1136/ard-2024-226176
Altered CD8+ T cell subpopulation in the bone marrow microenvironment of cynomolgus monkeys with spontaneous ankylosing spondylitis
doi : 10.1136/ard-2024-226018
Correspondence on ‘Current myositis clinical trials and tribulations’ by Saygin et al
doi : 10.1136/ard-2024-225751
Response to: Correspondence on ‘Current myositis clinical trials and tribulations’ by Saygin et al
doi : 10.1136/ard-2024-225762
Correspondence on ‘EULAR recommendations for the management of systemic lupus erythematosus: 2023 update’ by Fanouriakis et al
doi : 10.1136/ard-2024-226392
Response to: Correspondence on ‘EULAR recommendations for the management of systemic lupus erythematosus: 2023 update’ by Fanouriakis et al
doi : 10.1136/ard-2024-226636
Correspondence on ‘Risk of cardiovascular disease with high-dose versus low-dose use of non-steroidal anti-inflammatory drugs in ankylosing spondylitis’ by Kim et al
doi : 10.1136/ard-2024-226587
Correction: Ensuring tight control in patients with rheumatoid arthritis treated with targeted therapies during the COVID-19 pandemic using a telehealth strategy
